Background: The optimal way of adding anti-EGFR antibodies to chemotherapy in the first line treatment of advanced NSCLC is unknown. We performed two parallel randomised phase 2 studies, one with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results